Biocon Ltd
NSE:BIOCON
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
233.1
391.2
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one BIOCON stock under the Base Case scenario is 455.48 INR. Compared to the current market price of 331.5 INR, Biocon Ltd is Undervalued by 27%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Biocon Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for BIOCON cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Biocon Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Biocon Ltd
Balance Sheet Decomposition
Biocon Ltd
Current Assets | 151.8B |
Cash & Short-Term Investments | 14.1B |
Receivables | 72.6B |
Other Current Assets | 65.1B |
Non-Current Assets | 408.9B |
Long-Term Investments | 7.5B |
PP&E | 119.8B |
Intangibles | 266.6B |
Other Non-Current Assets | 15B |
Current Liabilities | 153.6B |
Accounts Payable | 68.2B |
Accrued Liabilities | 4.1B |
Short-Term Debt | 21.5B |
Other Current Liabilities | 59.9B |
Non-Current Liabilities | 209.3B |
Long-Term Debt | 134.2B |
Other Non-Current Liabilities | 75B |
Earnings Waterfall
Biocon Ltd
Revenue
|
148.9B
INR
|
Cost of Revenue
|
-49.3B
INR
|
Gross Profit
|
99.7B
INR
|
Operating Expenses
|
-84.7B
INR
|
Operating Income
|
15B
INR
|
Other Expenses
|
-625m
INR
|
Net Income
|
14.4B
INR
|
Free Cash Flow Analysis
Biocon Ltd
INR | |
Free Cash Flow | INR |
In the second quarter of fiscal 2025, Biocon reported a 4% revenue growth and an 8% increase when adjusted for one-time revenues. The biosimilars sector thrived, showing a 19% year-on-year rise, while generics faced challenges, declining 8%. Management anticipates recovery driven by new product launches, including a GLP-1 generic expected in the UK. The total revenue reached INR 3,623 crore. Despite flat overall performance, there were signs of growth in the second half, with an EBITDA margin of 20%. Significant debt refinancing improved financial flexibility, positioning Biocon for potential expansion and growth in the next phases.
What is Earnings Call?
BIOCON Profitability Score
Profitability Due Diligence
Biocon Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
Score
Biocon Ltd's profitability score is 52/100. The higher the profitability score, the more profitable the company is.
BIOCON Solvency Score
Solvency Due Diligence
Biocon Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
Biocon Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BIOCON Price Targets Summary
Biocon Ltd
According to Wall Street analysts, the average 1-year price target for BIOCON is 344.51 INR with a low forecast of 237.35 INR and a high forecast of 483 INR.
Dividends
Current shareholder yield for BIOCON is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
BIOCON Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Biocon Ltd. is a holding company, which engages in the manufacture, research, and development of therapeutic drugs. The company is headquartered in Bangalore, Karnataka and currently employs 3,203 full-time employees. The company went IPO on 2004-04-17. The firm is also focused on developing novel therapies for diabetes, oncology and immunology. The Company’s businesses segment includes Generics, Biosimilars, Novel Biologics and Research Services. The Company’s Generic Formulations and active pharmaceutical ingredients (API)products include Rosuvastatin, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company’s portfolio includes ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
Contact
IPO
Employees
Officers
The intrinsic value of one BIOCON stock under the Base Case scenario is 455.48 INR.
Compared to the current market price of 331.5 INR, Biocon Ltd is Undervalued by 27%.